-
公开(公告)号：EP2282719B1
公开(公告)日：2018-05-30
申请号：EP09739530.5
申请日：2009-04-27
IPC分类号： A61K9/00 , A61K31/573 , A61K33/00
CPC分类号： A61K31/573 , A61K33/00 , A61K2300/00
摘要： Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
-
公开(公告)号：EP2563121A1
公开(公告)日：2013-03-06
申请号：EP11775615.5
申请日：2011-04-29
IPC分类号： A01N39/00
CPC分类号： A61K31/58 , A61K9/0019 , A61K31/522 , A61K31/56 , A61K38/13 , A61K41/0004 , A61K45/06 , A61K2300/00
摘要： Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and/or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject.
-
公开(公告)号：EP2282719A2
公开(公告)日：2011-02-16
申请号：EP09739530.5
申请日：2009-04-27
IPC分类号： A61K9/00
CPC分类号： A61K31/573 , A61K33/00 , A61K2300/00
摘要： Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating inflammatory neurodegenerative condition or disease or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
摘要翻译： 提供了电动改变的流体（富含气体的电动流体）在用量足以提供对细胞膜电位和细胞膜电导率中的至少一个的调制在电荷稳定的含氧纳米结构的离子wässrige溶液的包含，和治疗性组合物和 使用方法在治疗炎性神经变性病症或疾病或其至少一种症状。 所述电动改变的流体或治疗性组合物和方法包括电动改变的流体ioinic与其它治疗剂组合OPTIONALLYwässrige。 特定方面提供一种用于调节或调控通过细胞膜，膜电位，膜蛋白的至少一个的调制与所述炎性应答相关的细胞内信号转导：例如膜受体，包括但不限于G蛋白偶联受体（GPCR），和 细胞间连接（例如，紧密连接，间隙连接，黏着带和桥粒）。 其他实施例包括用于电动改变的流体（例如，电动改变的富含气体的流体和溶液）和治疗组合物施用或式蒸发散的具体路线。
-
公开(公告)号：EP2083876A2
公开(公告)日：2009-08-05
申请号：EP07874431.5
申请日：2007-10-25
IPC分类号： A61M1/00
CPC分类号： A61K9/0048 , A61K9/0014 , A61K33/00 , A61K45/06 , A61L15/44 , A61L26/0066 , A61L2300/404 , A61L2300/412 , A61L2300/426 , B01F3/04531 , B01F3/0807 , B01F3/0853 , B01F7/00816 , B29D11/00038 , A61K2300/00
摘要： Particular embodiments disclosed herein relate to gas-enriched fluids, methods of making the same, systems for making the same and/or methods of treatment utilizing the gas-enriched fluids for wound care related conditions and/or diseases. In certain embodiments, the gas-enriched fluid is oxygen-enriched water. Certain embodiments relate to cosmetic and/or therapeutic fluids and/or methods of treatment utilizing the fluids in order to treat a cosmetic and/or therapeutic symptom of wound care and/or increase proper wound healing.
-
5.发明公开COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS 审中-公开组合物和方法胰岛素抵抗和糖尿病的治疗
公开(公告)号：EP2424507A1
公开(公告)日：2012-03-07
申请号：EP10770213.6
申请日：2010-04-27
IPC分类号： A61K9/14
CPC分类号： A61K9/0009 , A61K9/0014 , A61K9/08 , A61K31/58 , A61K33/00 , A61K45/06 , A61K47/02 , A61K2300/00
摘要： Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions.
-
6.发明公开COMPOSITIONS AND METHODS FOR TREATING MATRIX METALLOPROTEINASE 9 (MMP9)-MEDIATED CONDITIONS 审中-公开组合物和方法用于治疗基质金属蛋白酶-9（MMP-9）介导的疾病
公开(公告)号：EP2364154A1
公开(公告)日：2011-09-14
申请号：EP09822743.2
申请日：2009-10-22
IPC分类号： A61K31/74
CPC分类号： A61K31/00 , A61K9/0078 , A61K45/06
摘要： Provided are methods for treating an MMP9-mediated condition or disease, comprising administration of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating an MMP9-mediated condition or disease. The chargestabilized oxygen-containing nanostructures are preferably stably configured in the fluid in an amount sufficient to provide for modulation of cellular membrane potential and/or conductivity.
-
7.发明公开COMPOSITIONS AND METHODS FOR TREATING THYMIC STROMAL LYMPHOPOIETIN (TSLP)-MEDIATED CONDITIONS 审中-公开组合物和方法用于治疗TSLP介导的疾病
公开(公告)号：EP2350263A1
公开(公告)日：2011-08-03
申请号：EP09822721.8
申请日：2009-10-22
CPC分类号： A61K31/00 , A61K9/0078 , A61K45/06
摘要： Provided are methods for treating a TSLP-mediated or TSLPR-mediated disease or condition, comprising administration of an electrokinetically altered aqueous fluid comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures substantially having an average diameter of less than about 100 nanometers and stably configured in the ionic aqueous fluid in an amount sufficient for treating a TSLP-mediated or TSLPR-mediated disease or condition. The charge-stabilized oxygen-containing nanostructures are preferably stably configured in the fluid in an amount sufficient to provide for modulation of cellular membrane potential and/or conductivity. Certain aspects comprising modulation or down-regulation of TSLP expression and/or activity have utility for treating TSLP-mediated or TSLPR-mediated diseases or conditions as disclosed herein (e.g., disorders of the immune system, allergic inflammation, allergic airway inflammation, DC-mediated inflammatory Th2 responses, atopic dermatitis, atopic eczema, asthma, obstructive airways disease, chronic obstructive pulmonary disease, and food allergies, inflammatory arthritis, rheumatoid arthritis, psoriasis, IgE-mediated disorders, and rhino-conjunctivitis).
-
公开(公告)号：EP2285347A2
公开(公告)日：2011-02-23
申请号：EP09739731.9
申请日：2009-04-29
IPC分类号： A61K9/00
CPC分类号： A61K9/0087 , A61K33/00 , A61K45/06 , Y02A50/473 , Y02A50/475 , Y02A50/481 , Y02A50/491 , A61K2300/00
摘要： Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for using same in treating digestive disorders or at least one symptom thereof. The electrokinetically-altered fluid compositions and methods include electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said digestive disorders by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids and therapeutic compositions.
-
公开(公告)号：EP2224924A1
公开(公告)日：2010-09-08
申请号：EP08841991.6
申请日：2008-10-24
IPC分类号： A61K31/427 , A61P25/00
CPC分类号： C12N13/00 , A61K31/137 , A61K31/58 , A61K31/7036 , A61K33/00 , A61K33/14 , A61K45/06 , G01N33/6872 , A61K2300/00
摘要： Particular aspects provide electro kinetically-generated fluids (e.g., electro kinetically-generated gas-enriched fluids and solutions), and therapeutic compositions and methods comprising use thereof in treating at least one symptom of cystic fibrosis. In particular embodiments, at least one symptom of cystic fibrosis treated by the present invention include inhibition of Pseudomonas infection, synergy with tobramycin (including TOBI) for use against bacterial infection, and synergy with a bronchiodilator. In particular embodiments, the electro kinetically-generated fluids or therapeutic compositions and methods comprise combination with other therapeutic agents (e.g., antibiotics, albuterol, budesonide, etc.). In certain aspects, the methods comprise regulating or modulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G protein coupled receptors, and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes).
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.025 秒)
